Date: 2014-03-17
Type of information: Establishment of a new subsidiary in the EU
Compound: Transcend brain delivery platform
Company: MedImmune (USA - global biologics arm of AstraZeneca (UK) biOasis (Canada)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease: Transciend
Details: * On March 17, 2014, Bioasis Technologies, a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Under the terms of the agreement, MedImmune will evaluate the therapeutic effect of its pre-clinical assets with next-generation versions of biOasis\'s Transcend brain delivery platform.
Financial terms: Financial terms were not disclosed.
Latest news:
